Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.
Tricyclics are much better tolerated than their reputation suggests, and countdown 6 reasons to use them, from melancholic depression to irritable bowel syndrome.
When patients are not amenable to usual therapy, equine-assisted psychotherapy (EAP) might be a good option. In this podcast, we’ll talk about working with horses as an alternative to, or in conjunction with, traditional therapy.
To start a conversation about race, you need to know the lingo. We interview psychiatrist Kali Cyrus on internalized racism, microaggressions, implicit bias, and more.
Do anticholinergic medications increase the risk of long-term cognitive decline and dementia? In this podcast, we will review the latest research examining the relationship between anticholinergic medication use and cognitive decline.
ADHD is one of the most treatable conditions in psychiatry if patients adhere to medication regimens. So, why are parents so resistant to stimulant medications and how can we approach these misconceptions?
We often hear about the “Tarasoff warning” and the “duty to protect,” but what do these mean, and who was Tarasoff? In today’s episode, we’ll break down the Tarasoff rulings and how you can navigate the legal ambiguities surrounding our duty to protect.
Zuranolone is a neurosteroid that is inching its way toward FDA approval in depression. In some ways it’s similar to brexanolone (Zulresso) – the IV therapy approved in 2019 for postpartum depression – and in other ways it’s different.
1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
RSS
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
